Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882118 | 0.89 | DHODH (0.47) | DHODHS1PR1MBNL1GAAPDE10A | |
| SCHEMBL1888145 | 0.86 | AR (0.41) | DHODHARMBNL1PDK1GAA | |
| SCHEMBL1888175 | 0.86 | KMT2A (0.43) | MBNL1PIK3CDKDM4EALDH1A1ADORA2A | |
| SCHEMBL681072 | 0.84 | PIK3CD (0.50) | MBNL1GAAPDE10APIK3CDKDM4E | |
| SCHEMBL1883204 | 0.76 | MBNL1 (0.43) | DHODHMBNL1GAAPDE10APDE2A | |
| SCHEMBL10285584 | 0.75 | PIK3CD (0.41) | ARMBNL1PDE10APDE2APIK3CD | |
| SCHEMBL1887556 | 0.74 | PIK3CD (0.53) | PIK3CD | |
| SCHEMBL4435974 | 0.74 | KDM4E (0.45) | DHODHPDE10APDE2APIK3CDKDM4E | |
| SCHEMBL1877264 | 0.72 | KMT2A (0.43) | MBNL1GAAPIK3CDKDM4EALDH1A1 | |
| SCHEMBL3579340 | 0.71 | ALDH1A1 (0.62) | GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | DHODH 818/4885AR 4675/4885S1PR1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.